{"mainPropery":{"diseaseId":7296,"diseaseName":"Ovarian carcinosarcoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7296/ovarian-carcinosarcoma","synonyms":["Malignant mixed mullerian tumor of the ovary","Malignant mixed M端llerian tumor of the ovary","MMMT of the ovary","Ovarian malignant mixed M端llerian tumor","Ovarian malignant mixed epithelial mesenchymal tumor"],"synonyms-with-source":[{"name":"Malignant mixed mullerian tumor of the ovary"},{"name":"Malignant mixed M端llerian tumor of the ovary","source":"OrphaData.Org"},{"name":"MMMT of the ovary","source":"Orphanet"},{"name":"Ovarian malignant mixed M端llerian tumor","source":"Orphanet"},{"name":"Ovarian malignant mixed epithelial mesenchymal tumor","source":"Orphanet"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"213512"},{"identifierType":"UMLS","identifierId":"C0392998"}]},"diseaseCategories":[{"diseaseTypeId":10,"diseaseTypeName":"Female Reproductive Diseases","source":"Orphanet"},{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":319,"resourceName":"Ovarian Cancer Research Alliance","abbreviation":"","address1":"14 Pennsylvania Plaza, Suite 2110","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10122","country":"United States","phone":"212-268-1002","tty":"","tollFree":"866-399-6262","fax":"202-331-2292","email":"info@ocrahope.org","url":"https://ocrahope.org","freeText":""},{"resourceID":320,"resourceName":"National Ovarian Cancer Coalition","address1":"2501 Oak Lawn Avenue, Suite 435","address2":"","address3":"","address4":"","address5":"","city":"Dallas","state":"TX","zip":"75219 ","country":"United States","phone":"214-273-4200 ","tty":"","tollFree":"888-OVARIAN","fax":"214-273-4201 ","email":"nocc@ovarian.org","url":"http://www.ovarian.org/"},{"resourceID":859,"resourceName":"The Liddy Shriver Sarcoma Initiative","abbreviation":"","address1":"17 Bethea Drive","address2":"","address3":"","address4":"","address5":"","city":"Ossining","state":"NY","zip":"10562-1620 ","country":"United States","phone":"914-762-3251 ","tty":"","tollFree":"","fax":"","email":"","url":"http://sarcomahelp.org/","freeText":""},{"resourceID":3366,"resourceName":"Minnesota Ovarian Cancer Alliance","abbreviation":"","address1":"4604 Chicago Ave ","address2":"","address3":"","address4":"","address5":"","city":"Minneapolis","state":"MN","zip":"55407","country":"","phone":"612-822-0500","tty":"","tollFree":"","fax":"","email":"INFO@MNOVARIAN.ORG","url":"http://mnovarian.org/","freeText":""},{"resourceID":3727,"resourceName":"The Gynecological Carcinosarcoma Project","abbreviation":"GCS Project","address1":"2795 Estates Drive","address2":"","address3":"","address4":"","address5":"","city":"Park City","state":"UT","zip":"84060","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"info@gcsproject.org","url":"http://gcsproject.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=(ovarian%5BAll+Fields%5D+AND+(%22carcinosarcoma%22%5BMeSH+Terms%5D+OR+carcinosarcoma%5BText+Word%5D))+AND+(%222003%2F04%2F13%22%5BPDat%5D+%3A+%222008%2F04%2F10%22%5BPDat%5D)' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Ovarian carcinosarcoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Ovarian+carcinosarcoma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Ovarian carcinosarcoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=213512' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:6170' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2155,"resourceId":3362,"resourceName":"Multiple Facebook groups","descriptionText":"Visit the following Facebook groups related to Ovarian carcinosarcoma:<br />\r\n<a href='https://www.facebook.com/groups/carcinosarcoma/' target='_blank'>MMMT (Malignant Mixed Mullerian Tumor) aka Carcinosarcoma</a><br /><a href='https://www.facebook.com/TheGCSProject' target='_blank'>The GCS Project</a><br />","resourceClassificationName":"Organizations","resourceClassificationSectionName":"Social Networking Websites"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/ovarian-cancer' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":6377,"questionText":"What is ovarian carcinosarcoma?","answerText":"<strong>Ovarian carcinosarcoma</strong>, also known as a <a href=\"http://rarediseases.info.nih.gov/GARD/Condition/6966/Malignant_mixed_Mullerian_tumor.aspx\" target=\"_blank\">malignant mixed mullerian tumor</a> (MMMT) of the ovary, is a rare, aggressive&nbsp;<a href=\"http://www.cancer.gov/dictionary?CdrID=45333\" target=\"_blank\">cancer</a> of the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/9433.htm\" target=\"_blank\">ovary</a>&nbsp;with characteristics of two types of cancer: <a href=\"http://www.cancer.gov/dictionary?CdrID=45963\" target=\"_blank\">carcinoma</a>&nbsp;and <a href=\"http://www.cancer.gov/dictionary?CdrID=45562\" target=\"_blank\">sarcoma</a>.[5437] Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage.[13954] When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood.[13954] Treatment usually consists of <a href=\"http://www.cancer.gov/dictionary?CdrID=45570\" target=\"_blank\">surgery</a>&nbsp;to remove the tumor and <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=\"_blank\">chemotherapy</a>.[5437] The chance of recovery and long-term survival (prognosis) is poor, with a reported 5-year survival rate of about 28%.[13954]","dateModified":"2017-10-18T00:00:00"},"basicQuestions":[{"questionId":6829,"questionText":"Is ovarian carcinosarcoma inherited?","answerText":"Ovarian carcinosarcoma is not thought to be due to an inherited gene mutation.[5437]&nbsp; We are aware of one report of a woman with a&nbsp;<a href=\"http://ghr.nlm.nih.gov/gene/BRCA2\" target=\"_blank\"><em>BRCA2</em></a> gene mutation who developed ovarian carcinosarcoma.[5949] However, to our knowledge, this cancer typically occurs in women with no family history of ovarian carcinoma or a hereditary cancer syndrome.","dateModified":"2017-10-18T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":5437,"authors":"del Carmen MG, Birrer M, Schorge JO","articleTitle":"Carcinosarcoma of the ovary: a review of the literature","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"271-277","url":"http://www.ncbi.nlm.nih.gov/pubmed/22155675","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":5949,"authors":"Sonoda Y, Saigo PE, Federici MG, Boyd J","articleTitle":"Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2000","volume":"76","pages":"226-229","url":"http://www.ncbi.nlm.nih.gov/pubmed/10637076","dateAccessed":"2013-03-27T00:00:00"}]},{"questionId":6378,"questionText":"How might ovarian carcinosarcoma be treated?","answerText":"Because ovarian carcinosarcoma is rare, there are no established treatment guidelines.&nbsp; Treatment decisions are based on the unique features of each individual's diagnosis.[5437]&nbsp; The <a href=\"http://www.nccn.org/index.asp\" target=\"_blank\">National Comprehensive Cancer Network</a>&nbsp;(NCCN), a group of physicians and researchers who strive to improve cancer care, recommends that women with ovarian carcinosarcoma be treated similarly to women with ovarian carcinoma (also called <a href=\"http://www.cancer.gov/dictionary?CdrID=45683\" target=\"_blank\">epithelial ovarian cancer</a>), which is the most common type of ovarian cancer.[5438]<br />\r\n<br />\r\nCurrently, treatment for ovarian carcinosarcoma usually begins with surgery to remove as much of the cancer as possible.&nbsp; <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=\"_blank\">Chemotherapy</a>&nbsp;may be used to destroy any cancer cells that could be in the body after surgery.&nbsp; Medications that contain <a href=\"http://www.cancer.gov/dictionary?CdrID=45841\" target=\"_blank\">platinum</a> (such as&nbsp;<a href=\"http://www.cancer.gov/cancertopics/druginfo/cisplatin\" target=\"_blank\">cisplatin</a>&nbsp;or <a href=\"https://www.cancer.gov/about-cancer/treatment/drugs/carboplatin\" target=\"_blank\">carboplatin</a>) seem to be the most effective&nbsp;chemotherapies for&nbsp;ovarian carcinosarcoma.&nbsp; Recent evidence suggests that&nbsp;another medication called <a href=\"http://www.cancer.gov/cancertopics/druginfo/ifosfamide\" target=\"_blank\">ifosfamide</a> may increase the effectiveness of treatment when&nbsp;used in combination&nbsp;with platinum-based medications.[5437][5438]","dateModified":"2017-07-06T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":5437,"authors":"del Carmen MG, Birrer M, Schorge JO","articleTitle":"Carcinosarcoma of the ovary: a review of the literature","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"271-277","url":"http://www.ncbi.nlm.nih.gov/pubmed/22155675","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":5438,"authors":"National Comprehensive Cancer Network","articleTitle":"Ovarian Cancer","bookWebsiteJournalTitle":"NCCN Guidelines for Patients","date":"2017","volume":"","pages":"","url":"https://www.nccn.org/patients/guidelines/ovarian/index.html","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":6966,"relatedDiseaseName":"Malignant mixed Mullerian tumor","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":38773,"abbreviatedInquiry":"Is ovarian carcinosarcoma typically hereditary?&nbsp; My mother was recently diagnosed with this type of cancer.&nbsp; I'm wondering if ovarian carcinosarcoma with a primary sarcoma component is typically seen in genetic conditions.","caseQuestions":[{"questionId":6829,"questionText":"Is ovarian carcinosarcoma inherited?","answerText":"Ovarian carcinosarcoma is not thought to be due to an inherited gene mutation.[5437]&nbsp; We are aware of one report of a woman with a&nbsp;<a href=\"http://ghr.nlm.nih.gov/gene/BRCA2\" target=\"_blank\"><em>BRCA2</em></a> gene mutation who developed ovarian carcinosarcoma.[5949] However, to our knowledge, this cancer typically occurs in women with no family history of ovarian carcinoma or a hereditary cancer syndrome.","dateModified":"2017-10-18T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":5437,"authors":"del Carmen MG, Birrer M, Schorge JO","articleTitle":"Carcinosarcoma of the ovary: a review of the literature","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"271-277","url":"http://www.ncbi.nlm.nih.gov/pubmed/22155675","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":5949,"authors":"Sonoda Y, Saigo PE, Federici MG, Boyd J","articleTitle":"Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2000","volume":"76","pages":"226-229","url":"http://www.ncbi.nlm.nih.gov/pubmed/10637076","dateAccessed":"2013-03-27T00:00:00"}]}]},{"caseId":36345,"abbreviatedInquiry":"I am looking for recent information on ovarian carcinosarcoma and the chemotherapy regime that is most effective for treating this.","caseQuestions":[{"questionId":6377,"questionText":"What is ovarian carcinosarcoma?","answerText":"<strong>Ovarian carcinosarcoma</strong>, also known as a <a href=\"http://rarediseases.info.nih.gov/GARD/Condition/6966/Malignant_mixed_Mullerian_tumor.aspx\" target=\"_blank\">malignant mixed mullerian tumor</a> (MMMT) of the ovary, is a rare, aggressive&nbsp;<a href=\"http://www.cancer.gov/dictionary?CdrID=45333\" target=\"_blank\">cancer</a> of the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/imagepages/9433.htm\" target=\"_blank\">ovary</a>&nbsp;with characteristics of two types of cancer: <a href=\"http://www.cancer.gov/dictionary?CdrID=45963\" target=\"_blank\">carcinoma</a>&nbsp;and <a href=\"http://www.cancer.gov/dictionary?CdrID=45562\" target=\"_blank\">sarcoma</a>.[5437] Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage.[13954] When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of ovarian carcinosarcoma is not yet understood.[13954] Treatment usually consists of <a href=\"http://www.cancer.gov/dictionary?CdrID=45570\" target=\"_blank\">surgery</a>&nbsp;to remove the tumor and <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=\"_blank\">chemotherapy</a>.[5437] The chance of recovery and long-term survival (prognosis) is poor, with a reported 5-year survival rate of about 28%.[13954]","dateModified":"2017-10-18T00:00:00","references":[{"referenceId":5437,"authors":"del Carmen MG, Birrer M, Schorge JO","articleTitle":"Carcinosarcoma of the ovary: a review of the literature","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"271-277","url":"http://www.ncbi.nlm.nih.gov/pubmed/22155675","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13954,"authors":"Kim HJ, Lee HM, Kim MK, Lee YK, Lee IH, Lee KH, Kim H","articleTitle":"Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma","bookWebsiteJournalTitle":"Obstet Gynecol Sci","date":"July, 2017","volume":"60(4)","pages":"350-356","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547082/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":6378,"questionText":"How might ovarian carcinosarcoma be treated?","answerText":"Because ovarian carcinosarcoma is rare, there are no established treatment guidelines.&nbsp; Treatment decisions are based on the unique features of each individual's diagnosis.[5437]&nbsp; The <a href=\"http://www.nccn.org/index.asp\" target=\"_blank\">National Comprehensive Cancer Network</a>&nbsp;(NCCN), a group of physicians and researchers who strive to improve cancer care, recommends that women with ovarian carcinosarcoma be treated similarly to women with ovarian carcinoma (also called <a href=\"http://www.cancer.gov/dictionary?CdrID=45683\" target=\"_blank\">epithelial ovarian cancer</a>), which is the most common type of ovarian cancer.[5438]<br />\r\n<br />\r\nCurrently, treatment for ovarian carcinosarcoma usually begins with surgery to remove as much of the cancer as possible.&nbsp; <a href=\"http://www.cancer.gov/dictionary?CdrID=45214\" target=\"_blank\">Chemotherapy</a>&nbsp;may be used to destroy any cancer cells that could be in the body after surgery.&nbsp; Medications that contain <a href=\"http://www.cancer.gov/dictionary?CdrID=45841\" target=\"_blank\">platinum</a> (such as&nbsp;<a href=\"http://www.cancer.gov/cancertopics/druginfo/cisplatin\" target=\"_blank\">cisplatin</a>&nbsp;or <a href=\"https://www.cancer.gov/about-cancer/treatment/drugs/carboplatin\" target=\"_blank\">carboplatin</a>) seem to be the most effective&nbsp;chemotherapies for&nbsp;ovarian carcinosarcoma.&nbsp; Recent evidence suggests that&nbsp;another medication called <a href=\"http://www.cancer.gov/cancertopics/druginfo/ifosfamide\" target=\"_blank\">ifosfamide</a> may increase the effectiveness of treatment when&nbsp;used in combination&nbsp;with platinum-based medications.[5437][5438]","dateModified":"2017-07-06T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":5437,"authors":"del Carmen MG, Birrer M, Schorge JO","articleTitle":"Carcinosarcoma of the ovary: a review of the literature","bookWebsiteJournalTitle":"Gynecologic Oncology","date":"2012","volume":"125","pages":"271-277","url":"http://www.ncbi.nlm.nih.gov/pubmed/22155675","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":5438,"authors":"National Comprehensive Cancer Network","articleTitle":"Ovarian Cancer","bookWebsiteJournalTitle":"NCCN Guidelines for Patients","date":"2017","volume":"","pages":"","url":"https://www.nccn.org/patients/guidelines/ovarian/index.html","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Ovarian_carcinosarcoma"}